CMG190303
AssetAlso Dapagliflozin/Rosuvastatin
Fixed-dose combination of SGLT2 inhibitor dapagliflozin and HMG-CoA reductase inhibitor rosuvastatin
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- 2
- Indications
- 877
- Trials
- 1
- Developer
Indications
2Dyslipidemia
Phase 3, Recruiting, NCT06772168, clinicaltrials.gov, 7 Oct 2026
Type 2 diabetes
Phase 3, Recruiting, NCT06772168, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains5
- Owner and partners1
- Trials877
- Evidence for its targets5
- Competitors12
- Aging relevance1
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.